Successful Plasma Exchange to Remove Heparin-Induced-Thrombocytopenia Antibodies Prior to LVAD Implantation: A Case Series
Purpose: Published data on therapeutic plasma exchange (TPE) in patients with heparin induced thrombocytopenia (HIT) prior to left ventricular assist device (LVAD) implantation is limited. Here we describe a case series of patients with acute HIT who underwent TPE prior to LVAD implantation allowing the use of intraoperative heparin. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Ngo-Hamilton, B. Ramu, M. Mazepa, M. Reding, C. Martin, T. Alexy, J. Schultz, V. Maharaj, R. John, A. Shaffer, F. Kamdar, D. Garry, R. Cogswell Source Type: research
Heparin Free Zone: 100 Days of Impella 5.5 Support with Argatroban in a Patient with HIT
We describe a patient in acute cardiogenic shock with heparin induced thrombocytopenia (HIT) who was transitioned to an Impella 5.5 and supported for 100 days with argatroban and no heparin until heart transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: J.S. Newman, V. Demekhin, G.L. Piper, , O. Haddad, Z. Kon, C. Saikus Source Type: research
Management of HIT Prior to Heart Transplant on Temporary MCS
Introduction: Heparin-induced thrombocytopenia (HIT) is a concern in cardiac surgery patients, who routinely receive heparin during interventions. Diagnosis relies on detection of PF4 antibodies (Ab) and a functional serotonin-release assay (SRA). Treatment involves stopping heparin, but optimal management in future interventions requiring heparin remains unclear. This case presents the diagnosis, management, and surgical considerations of HIT in a heart transplant patient with temporary mechanical circulatory support (tMCS). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Guha, A. Bhimaraj, C.M. Martin, A. He, E.E. Suarez, L. Chou Source Type: research
A Blood Conservation Approach to Peri-Transplant Care Informed by Successful Heart Transplantation in a Jehovah ’s Witness
Introduction: Temporary circulatory support (TCS) is increasingly used to bridge patients to heart transplantation (HT). TCS can cause hemolysis and thrombocytopenia, and obligates anticoagulation use, increasing bleeding risk. Jehovah ’s Witnesses (JW) often decline blood products, challenging the use of TCS and precluding HT at many centers. Here, we present the case of a JW patient who underwent bloodless HT after a period of TCS and describe a new, broadly applicable peri-transplant blood conservation protocol. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: A. Oseran, K. Brown, , D. Zlotoff, B. Yang, I. Mastoris, M. Doucette, E. Michel, C. Newton-Cheh, A. Bagchi, R. Pierson, D. D'Alessandro, G. Lewis Source Type: research
Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
AbstractThrombosis is one of the many signs of antiphospholipid syndrome (APS) and COVID-19 infection. Although the mechanisms contributing to thrombosis in APS and COVID-19 are relatively similar, this remains an open subject. Even now (when the COVID-19 pandemic has subsided), there is no conclusive solution to APS and COVID-19 co-occurrence. The presence of newly generated antiphospholipid antibodies (aPLs) in COVID-19 infection may or may not be connected to the diagnosis of APS. The prevalence of aPLs is substantial in severe COVID-19 but not related to thrombosis or a worse outcome. Adequate monitoring of antibody po...
Source: Rheumatology International - March 30, 2024 Category: Rheumatology Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Clinical Outcome and its Predictors in Children With Newly Diagnosed Immune Thrombocytopenia
CONCLUSION: The rate of chronicity and intracranial bleeding in our cohort is more than the reported rates in literature. Higher ALC was found to be associated with response.PMID:38554005 (Source: Indian Pediatrics)
Source: Indian Pediatrics - March 30, 2024 Category: Pediatrics Authors: Parameswary Singaravadivelu Jaikumar Govindaswamy Ramamoorthy C G Delhi Kumar Source Type: research
Revealing cyclic thrombocytopenia: The role of periodogram analysis and the impact of thrombopoietin receptor agonist therapy
Int J Lab Hematol. 2024 Mar 29. doi: 10.1111/ijlh.14278. Online ahead of print.NO ABSTRACTPMID:38551036 | DOI:10.1111/ijlh.14278 (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - March 29, 2024 Category: Hematology Authors: Atsushi Isoda Hiroaki Kurashina Reo Usami Yukie Terasaki Naoki Akashi Masahiro Mihara Hirono Iriuchishima Akio Saito Morio Matsumoto Morio Sawamura Source Type: research
Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management
CONCLUSION: Two of 4 patients with VITT developed refractory thrombocytopenia successfully treated with intravenous immunoglobulin, corticosteroids, and plasma exchange therapy. Patients with VITT remained on anticoagulation for at least 9 months due to persistently positive diagnostic tests. Four of 5 patients with immune thrombocytopenia received intravenous immunoglobulin and corticosteroids with good recovery. Patients who received a subsequent COVID-19 mRNA vaccine had no adverse hematologic effects.PMID:38550529 | PMC:PMC10973182 | DOI:10.1016/j.rpth.2024.102357 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: M Ge D Ladha J Lymer S Pancic M Carrier G Le Gal L A Castellucci Source Type: research
α2,6-sialic Acid on the Platelet Membrane Surface is a Novel Biomarker and Therapeutic Target in Children with Primary Immune Thrombocytopenia
CONCLUSION: The sialylation of platelet membrane glycoprotein is abnormally expressed in primary immune thrombocytopenia. The sialylation of platelet membrane glycoprotein may be involved in the occurrence and development of the disease. It is of great practical significance to diagnose and evaluate the therapeutic effect of the disease by detecting the sialylation of platelet membrane glycoprotein.PMID:38551414 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Jingxin Gong Zhaoyang Liu Wenjuan Wang Cuimin Zhu Chen Li Source Type: research
